secwatch / observer
8-K filed August 7, 2023, 7:59 PM ET CIK 0001600132
leadership confidence high sentiment neutral materiality 0.55

Bellerophon CEO Peter Fernandes and VP Parag Shah to depart under separation agreements

Bellerophon Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Fernandes

Chief Executive Officer
Bellerophon Therapeutics, Inc.
Effective
2023-11-15
Filed
August 7, 2023, 7:59 PM ET
On August 3, 2023, Bellerophon Therapeutics, Inc. (the “Company”) entered into a transition and separation agreement with Peter Fernandes, the Company’s Chief Executive Officer
Departed

Parag Shah

Vice President of Business Operations
Bellerophon Therapeutics, Inc.
Effective
2023-08-31
Filed
August 7, 2023, 7:59 PM ET
and a transition and separation agreement with Parag Shah, the Company’s Vice President of Business Operations

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..

Action
separated
Role
Chief Executive Officer
Exact text from the filing
On August 3, 2023, Bellerophon Therapeutics, Inc. (the “Company”) entered into a transition and separation agreement with Peter Fernandes, the Company’s Chief Executive Officer
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..

Action
separated
Role
Vice President of Business Operations
Exact text from the filing
and a transition and separation agreement with Parag Shah, the Company’s Vice President of Business Operations
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-23-088330
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.